시장보고서

상품코드

1877452

세계의 CAR-T 세포치료 시장 : 제품 유형별, 표적 항원별, 적응증별, 최종사용자별, 국가별, 지역별 - 산업 분석, 시장 규모, 점유율 및 예측(2025-2032년)

CAR T-cell Therapy Market, By Product Type, By Target Antigen, By Indication, By End user, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

발행일: 2025년 11월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 365 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

CAR-T 세포치료 시장 규모는 2024년 56억 7,800만 달러로 평가되었고, 2025년부터 2032년까지 연평균 38.5%의 성장률을 보일 것으로 예측됩니다.

CAR-T 세포치료는 환자의 T세포를 변형시켜 암세포를 표적으로 공격, 파괴하는 유전자변형 면역세포치료법입니다. 특히 특정 혈액암에 효과적이며, 고형암에 대한 적용도 확대되고 있습니다. 재발성 또는 난치성 혈액악성종양에 대한 확실한 임상결과, 연구 파이프라인의 확대, 규제당국의 승인 증가, 바이오의약품 및 특수세포치료제 제조업체의 투자 증가로 인해 시장은 빠르게 성장하고 있습니다. 복잡한 제조 공정, 전문 치료 센터의 필요성, 고가의 치료비 등의 문제가 있지만, 제조 규모 확대, 파트너십, 차세대 자동차 설계가 상업적 확장을 촉진하고 있습니다.

CAR-T 세포 치료 시장 역학

임상적 유효성 향상 및 지속적 완화 효과

CAR-T 세포치료는 재발성 또는 난치성 혈액암 환자에서 임상적 유효성 향상과 지속적 관해를 실현하고 있습니다. 임상시험 및 실제 임상에서 확실한 성과로 다른 치료법이 효과를 나타내지 못한 경우에도 장기적인 반응을 얻을 수 있는 것으로 나타났으며, 이는 의사의 채용 촉진, 고가의 치료비 보험 적용 촉진, 적응증 확대 및 생산 규모 확대를 목표로 하는 제약사 및 제조업체의 투자 유치로 이어지고 있습니다. 투자 유치로 이어지고 있습니다.

CAR-T 세포치료제 시장 : 세분화 분석

세계 CAR-T 세포치료 시장은 제품 유형, 표적 항원, 적응증, 최종 사용자, 지역별로 세분화되어 있습니다.

제품 유형에 따라 시장은 아베크마, 브레이안지, 카비크티, 킴리아, 테카르타스, 예스카르타, 기타 등 7개 카테고리로 나뉩니다. 킴리아, 예스카르타와 같은 기존 제품들은 더 일찍부터 광범위한 임상 경험, 승인 실적, 그리고 더 큰 상업적 기반을 바탕으로 현재 시장을 선도하고 있습니다.

표적 항원별로 시장은 다시 CD19, BCMA(B세포 성숙 항원), CD22, GD2, HER2, GPC3, 기타(예: EGFRvIII, CD7, CD7, CD123, 메소세린) 등 7가지 카테고리로 분류됩니다. CD19는 B세포성 백혈병과 림프종에서 성공을 거둔 덕분에 현재도 이 분야에서 지배적인 카테고리입니다. BCMA는 다발성골수종에 대한 강력한 반응과 제품 출시 증가로 가장 빠르게 성장하고 있는 카테고리입니다.

적응증별로는 급성 림프모구백혈병, 림프종, 다발성 골수종, 맨틀세포 림프종 등 4가지 범주로 나뉩니다. 다발성골수종은 여러 BCMA CAR가 시장에 진입하고 있어 단기적으로 가장 높은 성장 잠재력을 가지고 있습니다. 고형암은 장기적으로 가장 큰 기회이지만, 상업화를 지연시키는 심각한 과학적, 중개적 문제에 직면해 있습니다. 혈액악성종양(급성림프모구백혈병, 각종 림프종, 다발성골수종)은 대부분의 승인과 임상의사의 경험이 집중되어 있기 때문에 단기적으로 수익과 채용을 주도할 것입니다.

최종 사용자별로는 병원 및 전문 암 치료 센터가 포함됩니다. CAR-T 치료는 전문적인 인프라, 입원 환자 모니터링 및 다직종 팀이 필요하기 때문에 이들 기관이 주요 치료 거점이 될 수 있습니다. 이들 센터가 현재 치료 건수의 대부분을 차지할 것으로 예측됩니다.

CAR-T 세포치료 시장 - 지역별 분석

북미, 특히 미국은 강력한 생명공학 투자, 확립된 임상시험 인프라, 유리한 상환 정책으로 인해 가장 큰 시장입니다. 유럽은 도입이 확대되고 있지만, 각국의 상환 상황은 다양합니다. 아시아태평양은 의료비 지출 증가, 중국, 일본, 한국의 임상 역량 확대, 현지 생산 증가로 인해 고성장 지역이지만, 일부 국가에서는 접근성과 가격 책정이 장벽으로 작용하고 있습니다.

CAR-T 세포치료제 시장 : 경쟁 구도

경쟁 구도는 승인된 CAR-T 제품을 보유한 대형 바이오텍/제약사와 차세대 치료제 및 동종 이식 치료제를 개발하는 다수의 소규모 혁신기업 및 학술 스핀오프 기업들로 구성되어 있으며, 임상 결과, 안전성(사이토카인 방출 증후군/신경독성 감소), 생산 규모 및 비용, 생산 및 유통을 위한 상업적 제휴가 경쟁의 초점이 되고 있습니다. 파이프라인과 생산능력을 확보하기 위한 기업 간 M&A, 라이선싱, 전략적 제휴가 빈번하게 이루어지고 있습니다.

서론
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카(LATAM)
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카(MEA)
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 튀르키예
- 알제리
- 이집트
- 기타

제12장 주요 벤더 분석 : CAR-T 세포치료 업계

경쟁 대시보드
- 경쟁 벤치마킹
- 경쟁 포지셔닝
기업 개요
- XX
- 기타

제13장 AnalystView의 전방위적 분석

LSH 25.12.22

CAR T-cell Therapy Market size was valued at US$ 5,678 Million in 2024, expanding at a CAGR of 38.5% from 2025 to 2032.

The CAR T-cell therapy involves engineered immune cell treatments that modify a patient's T cells which targets and then kills cancer cells, Specifically for certain blood cancers and is increasingly explored for solid tumors. The market is rapidly expanding due to robust clinical outcomes in relapsed or refractory hematologic malignancies, expanded research pipelines, increasing regulatory approvals, and increasing investment from biopharma and specialty cell therapy manufacturers. Complex manufacturing, the need for specialized treatment centers and High treatment costs, pose challenges, but manufacturing scale-up, partnerships and next-generation CAR designs are helping commercial expansion.

CAR T-cell Therapy Market- Market Dynamics

Improved Clinical Efficacy and Durable Remissions

CAR Tcell therapy has improved clinical efficacy and lasting remissions in patients with relapsed or refractory blood cancers. Strong results from clinical trials and real-world use have shown the treatment can produce long-term responses where other therapies failed, which encourages doctors to adopt it, motivates payers to cover the high costs, and attracts investment from pharmaceutical companies and manufacturers eager to expand indications and scale production.

CAR T-cell Therapy Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 38.5% over the forecast period (2025-2032)

Based on product type segmentation, Kymriah was predicted to show maximum market share in the year 2024

Based on target antigen segmentation, CD19 was the leading target antigen in 2024

Based on Indication segmentation, acute lymphoblastic leukemia was the leading indication segment in 2024

Based on end user segmentation, Cancer treatment centres was the leading indication segment in 2024

On the basis of region, North America was the leading revenue generator in 2024

CAR T-cell Therapy Market- Segmentation Analysis:

The Global CAR T-cell Therapy Market is segmented on the basis of Product Type, Target Antigen, Indication, End user, and Region.

The market is divided into seven categories based on product type: Abecma, Breyanzi, Carvykti, Kymriah, Tecartus, Yescarta and Others. The Established products like Kymriah and Yescarta lead the market at present because of earlier broader clinical experience, approvals, and larger commercial footprints.

For the Target Antigen the market is divided into again seven categories: CD19, BCMA (B-cell Maturation Antigen), CD22, GD2, HER2, GPC3 and Others (e.g., EGFRvIII, CD7, CD123, mesothelin). CD19 remains the dominant category in this segment today, driven by established success in B-cell leukemias and lymphomas. BCMA is the fastest growing category due to the strong responses in multiple myeloma and increasing product launches.

In By Indication segment there are four categories: Acute lymphoblastic leukemia, Lymphoma, Multiple Myeloma and Mantle Cell Lymphoma. Multiple myeloma represents the highest near-term upside due to multiple BCMA CARs entering the market. Solid tumors are the largest long-term opportunity but face substantial scientific and translational hurdles that will slow commercialization. Hematologic malignancies (acute lymphoblastic leukemia, various lymphomas, and multiple myeloma) will continue to drive near-term revenue and adoption because most approvals and clinician experience are concentrated here.

The End User segments includes Hospitals and specialized cancer treatment centers these are the primary sites of care because CAR T therapies need specialized infrastructure, inpatient monitoring, and multidisciplinary teams; these centers will capture the majority of current volume.

CAR T-cell Therapy Market- Geographical Insights

North America, particularly the United States, is the largest market due to strong biotech investment, established clinical trial infrastructure, and favorable reimbursement policies; Europe follows with growing adoption but variable national reimbursement landscapes; Asia-Pacific is a high-growth region driven by rising healthcare spending, expanding clinical capabilities in China, Japan, and South Korea, and increasing local manufacturing, though access and pricing remain barriers in some countries.

CAR T-cell Therapy Market- Competitive Landscape:

The competitive landscape is led by a mix of large biotech/pharma companies with approved CAR T products and numerous smaller innovators and academic spinouts developing next-generation and allogeneic therapies; competition centers on clinical performance, safety (reduced cytokine release syndrome/neurotoxicity), manufacturing scale and cost, and commercial partnerships for manufacturing and distribution, with M&A, licensing deals, and strategic alliances common as companies move to secure pipelines and production capacity.

Recent Developments:

On November 5, 2025, Prime Minister Narendra Modi unveiled three Indian innovations at ESTIC2025: QSIP, a 25-qubit QPU, and NexCAR19 - India's first indigenous CAR-T therapy by ImmunoACT. DBT and BIRAC supported development and funded a 200L GMP lentiviral production platform expected to serve about 1,000 patients a year. Ongoing DBT/BIRAC funding also supports wider CAR-T research for blood and solid tumors.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CAR T-CELL THERAPY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

ALLOGENE THERAPEUTICS
Aurora Biopharma
Bristol-Myers Squibb company
Cartesian Therapeutics, Inc.
Curocell Inc
Gilead Sciences
Johnson & Johnson Services, Inc.
JW Therapeutics
Lonza
Novartis
Others

GLOBAL CAR T-CELL THERAPY MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

Abecma
Breyanzi
Carvykti
Kymriah
Tecartus
Yescarta
Others

GLOBAL CAR T-CELL THERAPY MARKET, BY TARGET ANTIGEN- MARKET ANALYSIS, 2019 - 2032

CD19
BCMA (B-cell Maturation Antigen)
CD22
GD2
HER2
GPC3
Others (e.g., EGFRvIII, CD7, CD123, mesothelin)

GLOBAL CAR T-CELL THERAPY MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

Acute lymphoblastic leukemia
Lymphoma
Multiple Myeloma
Mantle Cell Lymphoma

GLOBAL CAR T-CELL THERAPY MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Cancer Treatment Centers
Others

GLOBAL CAR T-CELL THERAPY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. CAR T-cell Therapy Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. CAR T-cell Therapy Market Snippet by Product Type
- 2.1.2. CAR T-cell Therapy Market Snippet by Target Antigen
- 2.1.3. CAR T-cell Therapy Market Snippet by Indication
- 2.1.4. CAR T-cell Therapy Market Snippet by End user
- 2.1.5. CAR T-cell Therapy Market Snippet by Country
- 2.1.6. CAR T-cell Therapy Market Snippet by Region
2.2. Competitive Insights

3. CAR T-cell Therapy Key Market Trends

3.1. CAR T-cell Therapy Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. CAR T-cell Therapy Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. CAR T-cell Therapy Market Opportunities
3.4. CAR T-cell Therapy Market Future Trends

4. CAR T-cell Therapy Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. CAR T-cell Therapy Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. CAR T-cell Therapy Market Landscape

6.1. CAR T-cell Therapy Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. CAR T-cell Therapy Market - By Product Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Product Type, 2024 & 2032 (%)
- 7.1.2. Abecma
- 7.1.3. Breyanzi
- 7.1.4. Carvykti
- 7.1.5. Kymriah
- 7.1.6. Tecartus
- 7.1.7. Yescarta
- 7.1.8. Others

8. CAR T-cell Therapy Market - By Target Antigen

8.1. Overview
- 8.1.1. Segment Share Analysis, By Target Antigen, 2024 & 2032 (%)
- 8.1.2. CD19
- 8.1.3. BCMA (B-cell Maturation Antigen)
- 8.1.4. CD22
- 8.1.5. GD2
- 8.1.6. HER2
- 8.1.7. GPC3
- 8.1.8. Others (e.g., EGFRvIII, CD7, CD123, mesothelin)

9. CAR T-cell Therapy Market - By Indication

9.1. Overview
- 9.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
- 9.1.2. Acute lymphoblastic leukemia
- 9.1.3. Lymphoma
- 9.1.4. Multiple Myeloma
- 9.1.5. Mantle Cell Lymphoma

10. CAR T-cell Therapy Market - By End user

10.1. Overview
- 10.1.1. Segment Share Analysis, By Target Antigen, 2024 & 2032 (%)
- 10.1.2. Hospitals
- 10.1.3. Cancer Treatment Centers
- 10.1.4. Others

11. CAR T-cell Therapy Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. CAR T-cell Therapy Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. CAR T-cell Therapy Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.3.9. UK
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. UK Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.9.4. UK Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.3.9.5. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.9.6. UK Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.3.10. France
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.10.4. France Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.3.10.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.10.6. France Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.3.11. Italy
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.11.4. Italy Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.3.11.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.11.6. Italy Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.3.12. Spain
  - 11.3.12.1. Overview
  - 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.3. Spain Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Spain Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.12.6. Spain Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.3.13. The Netherlands
  - 11.3.13.1. Overview
  - 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.3. The Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.13.4. The Netherlands Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.3.13.5. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.13.6. The Netherlands Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Overview
  - 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.14.6. Sweden Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.3.15. Russia
  - 11.3.15.1. Overview
  - 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.3. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Russia Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.15.6. Russia Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.3.16. Poland
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Poland Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Poland Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.3.17. Rest of Europe
  - 11.3.17.1. Overview
  - 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.17.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.17.4. Rest of the Europe Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.3.17.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.17.6. Rest of the Europe Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. CAR T-cell Therapy Key Manufacturers in Asia Pacific
- 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 11.4.5. APAC Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
- 11.4.6. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.4.7. APAC Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.4.8. China
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.8.4. China Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.4.8.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.8.6. China Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.4.9. India
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.9.4. India Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.4.9.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.9.6. India Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.4.13. Indonesia
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Indonesia Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Indonesia Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.4.14. Thailand
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Thailand Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Thailand Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
- 11.5.1. Overview
- 11.5.2. CAR T-cell Therapy Key Manufacturers in Latin America
- 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 11.5.5. LATAM Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
- 11.5.6. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.5.7. LATAM Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa (MEA)
- 11.6.1. Overview
- 11.6.2. CAR T-cell Therapy Key Manufacturers in Middle East and Africa
- 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 11.6.5. MEA Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
- 11.6.6. MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.6.7. MEA Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- CAR T-cell Therapy Industry

12.1. Competitive Benchmarking
- 12.1.1. Competitive Dashboard
- 12.1.2. Competitive Positioning
12.2. Company Profiles
- 12.2.1. XX
- 12.2.2. Others

13. 360 Degree AnalystView

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us